Skip to main content

Mevalonate kinase deficiency

Mevalonate kinase deficiency is a condition characterised by recurrent episodes of fever, which typically begin during infancy. Each episode of fever lasts about 3 to 6 days, and the frequency of the episodes varies among affected individuals. In childhood the fevers seem to be more frequent, occurring as often as 25 times a year, but as the individual gets older the episodes occur less often.

Description

Mevalonate kinase deficiency is a condition characterised by recurrent episodes of fever, which typically begin during infancy. Each episode of fever lasts about 3 to 6 days, and the frequency of the episodes varies among affected individuals. In childhood the fevers seem to be more frequent, occurring as often as 25 times a year, but as the individual gets older the episodes occur less often.

Mevalonate kinase deficiency has additional signs and symptoms, and the severity depends on the type of the condition. There are two types of mevalonate kinase deficiency: a less severe type called hyperimmunoglobulinemia D syndrome (HIDS) and a more severe type called mevalonic aciduria (MVA).

During episodes of fever, people with HIDS typically have enlargement of the lymph nodes (lymphadenopathy), abdominal pain, joint pain, diarrhea, skin rashes, and headache. Occasionally they will have painful sores called aphthous ulcers around their mouth. In females, these may also occur around the vagina. Rarely, people with HIDS develop a buildup of protein deposits (amyloidosis) in the kidneys that can lead to kidney failure. Fever episodes in individuals with HIDS can be triggered by vaccinations, surgery, injury, or stress. Most people with HIDS have abnormally high levels of immune system proteins called immunoglobulin D (IgD) and immunoglobulin A (IgA) in the blood. It is unclear why some people with HIDS have high levels of IgD and IgA and some do not. Elevated levels of these immunoglobulins do not appear to cause any signs or symptoms. Individuals with HIDS do not have any signs and symptoms of the condition between fever episodes and typically have a normal life expectancy.

People with MVA have signs and symptoms of the condition at all times, not just during episodes of fever. Affected children have developmental delay, problems with movement and balance (ataxia), recurrent seizures (epilepsy), progressive problems with vision, and failure to gain weight and grow at the expected rate (failure to thrive). Individuals with MVA typically have an unusually small, elongated head. In childhood or adolescence, affected individuals may develop eye problems such as inflammation of the eye (uveitis), a blue tint in the white part of the eye (blue sclera), an eye disorder called retinitis pigmentosa that causes vision loss, or clouding of the lens of the eye (cataracts). Affected adults may have short stature and may develop muscle weakness (myopathy) later in life. During fever episodes, people with MVA may have an enlarged liver and spleen (hepatosplenomegaly), lymphadenopathy, abdominal pain, diarrhea, and skin rashes. Children with MVA who are severely affected with multiple problems may live only into early childhood; mildly affected individuals may have a normal life expectancy.

Inheritance patterns

The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.

Other names

Hyper IgD syndrome

Hyperimmunoglobulin D with periodic fever

Hyperimmunoglobulinemia D

Mevalonic aciduria

Mevalonicaciduria

Periodic fever, Dutch type

Patient picks for Genetic conditions

Related patient information and medicines

Glycogen storage disorders

Patient information leaflet

Glycogen storage disorders

Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.

Liver function tests

Patient information leaflet

Liver function tests

Cr... Causes of mild rises in transferases These include: Non-alcoholic fatty liver disease (the most common cause). Chronic hepatitis C infection. Sarcoidosis Bone fractures. Paget's disease of bone Paget's disease of bone. Osteomalacia Vitamin D deficiency. Primary sclerosing cholangitis Primary sclerosing cholangitis. Primary biliary.

Chronic myeloid leukaemia

Patient information leaflet

Chronic myeloid leukaemia

Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. What is chronic myeloid leukaemia. Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. CML develops due.

Anaemia

Patient information leaflet

Anaemia

Anaemia means that you have fewer red blood cells than normal or you have less haemoglobin than normal in each red blood cell. In either case, a reduced amount of oxygen is carried around in the bloodstream. And problems with the chemicals (or enzymes) that help the blood cell do its job, such as G6PD deficiency and pyruvate kinase deficiency..

Gastrointestinal malabsorption

Patient information leaflet

Gastrointestinal malabsorption

Gastrointestinal malabsorption syndrome means a failure to fully absorb digested foods from the gut (bowel) into your body. There are many different causes. Prolonged intestinal malabsorption may cause problems because of a lack of carbohydrates, proteins, fats, minerals and vitamins that are essential to keep you healthy. The treatment will.

Duchenne muscular dystrophy

Patient information leaflet

Duchenne muscular dystrophy

DNA testing and specialised genetic advice can help to find out whether the Duchenne gene is carried by other members of the family. What are the symptoms of Duchenne muscular dystrophy. Gene therapy The National Institute for Health and Care Excellence (NICE) approved the use of ataluren in 2023. Although this has not been in use for long, it.

Further reading and references

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 4 Mar 2026 | Latest version
  • 1 Apr 2011 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online pharmacy, treatments and health services

Simple access to trusted treatments and health services online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.